COMPANY

Coya Therapeutics

HQ: Houston, TX source · coyatherapeutics.com ↗ · Southwest

Keywords: cell therapy Amyotrophic Lateral Sclerosis COYA 302

Location: Houston, TX · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Jan 30, 2026 Raise Private placement: $11.1M (total, as published), announced Jan 30, 2026. Source: SEC filing. source ↗
Oct 24, 2025 Raise Follow-on offering: $20M (total, as published), announced Oct 24, 2025. Source: SEC filing. source ↗
Oct 1, 2025 Trial start Phase 2/Phase 3: Study of COYA 302 for the Treatment of ALS source ↗
Oct 22, 2024 Raise Private placement: $10M (total, as published), announced Oct 22, 2024. Source: SEC filing. source ↗

2027-01 (ESTIMATED) · Phase 2/Phase 3 · Study of COYA 302 for the Treatment of ALS · NCT07161999

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $41.1M. Last 2 years.

Jan 30, 2026 Private placement: $11.1M (total, as published), announced Jan 30, 2026. Source: SEC filing. source ↗
Oct 24, 2025 Follow-on offering: $20M (total, as published), announced Oct 24, 2025. Source: SEC filing. source ↗
Oct 22, 2024 Private placement: $10M (total, as published), announced Oct 22, 2024. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07161999	Study of COYA 302 for the Treatment of ALS	Phase 2/Phase 3	Recruiting	Oct 1, 2025	2027-01 (estimated)

Form D raises come from the company’s own SEC filing (last 2 years).

2024-10-28 Raise Private raise (SEC Form D): $10.0M sold; issuer “Coya Therapeutics, Inc.”. Verified from the SEC filing. SEC filing ↗